An interventional study of Oxytocin and Carbetocin in Post Partum Hemorrhage, sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing oxytocin in Postpartum Hemorrhage — 8 open to participants now, 9 under way, 1 of them phase 3. Oxytocin · Postpartum Hemorrhage.
Among the 64 studies testing oxytocin in Postpartum Hemorrhage, this one is the 26th largest by planned enrollment, is one of 3 that started in 2025, is one of 37 with no phase, and was the 57th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →8 of the 64 studies testing oxytocin in Postpartum Hemorrhage are open now, in 4 countries. Recruiting first, the newest first:
Mansoura University · Sites in Saudi Arabia
Ages 18–45 · Women only
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–40 · Women only · Healthy volunteers
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–50 · Women only · Healthy volunteers
Khyber Girls Medical College · Sites in Pakistan
Ages 18–40 · Women only
Assiut University
Ages 18–45 · Women only
By country, each count listing its studies:
Oxytocin: first FDA approval 1980 (SYNTOCINON). What it is approved for, and how studies give it, is on its page →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 8 · Phase 4 9
First in 2002; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is close to the median of 148 across 362 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 108 across the 64 interventional studies. Of the 42 that completed or were terminated, 4 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 64 have an industry lead sponsor. The 10 most frequent:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital is the lead sponsor of 138 studies on the registry; 17 are open to participants now.
34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital: 5 open now, 6 under way, none of them phase 3. Of 28 finished, 0 (0%) have results posted.
Among the 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital, this one is the 2nd largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2025, is one of 32 with no phase, and was the 31st registered.
Samuel Lunenfeld Research Institute, Mount Sinai Hospital’s Postpartum Hemorrhage studies by the year they started, since 2007.
4 of the studies testing oxytocin in Postpartum Hemorrhage that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05290129Samuel Lunenfeld Research Institute, Mount Sinai HospitalOxytocin Maintenance Infusion in Labouring Women Undergoing Cesarean Delivery: an Up-down Sequential Allocation Study | 2026-12 |
| NCT06333340Samuel Lunenfeld Research Institute, Mount Sinai HospitalComparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery | 2026-12 |
| NCT07784478Khyber Girls Medical CollegeEffect of Oxytocin Bolus Versus Slow Infusion on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia | 2027-04-01 |
| NCT06930391Samuel Lunenfeld Research Institute, Mount Sinai HospitalEffect of Extracellular Calcium on Carbetocin Mediated Contractility in Human Myometrium | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 64 studies testing oxytocin in Postpartum Hemorrhage, from their registry updates:
Among Samuel Lunenfeld Research Institute, Mount Sinai Hospital’s 34 in Postpartum Hemorrhage:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to compare 2 medications that are commonly used to prevent excess uterine bleeding (postpartum hemorrhage, or PPH) following cesarean delivery (CD), oxytocin and carbetocin. Most of the trials evaluating the preventative role of oxytocin and carbetocin after CD have focused on patient with low-risk of PPH.
This trial will focus on patients that are at increased risk of PPH, with risk factors such as: multiple gestation (twins, or more multiples), large baby, polyhydramnios (excess amniotic fluid), history of PPH, body mass index greater than 40, diabetes mellitus, hypertension, and placenta previa.
The investigators hypothesize that carbetocin would be more effective than an oxytocin regimen in reducing the risk of PPH in patients undergoing CD with any of the biological high-risk factors.
Postpartum hemorrhage (PPH) is a potentially life-threatening complication and one of the leading causes of maternal mortality. It has been estimated that one in every five maternal deaths occurs due to PPH globally. Primary PPH is predominantly caused by uterine atony or inadequate contraction of the uterus after childbirth. Active management of the third stage of labor involves prophylactic administration of a uterotonic agent before delivery of the placenta, as well as delayed cord clamping and controlled traction of the umbilical cord. The uterotonic administration remains the most essential component in terms of preventing PPH.
Oxytocin, a synthetic pituitary hormone, is the most commonly used first-line uterotonic drug. However, because of the short half-life (3-17 min), a continuous intravenous infusion is necessary to maintain uterotonic activity. Carbetocin is a synthetic oxytocin analog that binds with a similar affinity to the oxytocin receptors in the myometrium. Carbetocin produces stronger and more sustained action compared to oxytocin and has a longer half-life than oxytocin, thus reducing the requirement for an infusion after the initial dose. Recently published guidelines from the Society of Obstetrics and Gynecology (SOGC) have stated that Carbetocin should be considered as a first-line agent for the prevention of PPH after cesarean delivery (CD). The international consensus statement on the use of uterotonic agents has also recommended carbetocin as an alternative to oxytocin infusion during CD due to its longer duration of action.
Trials comparing carbetocin with oxytocin in CD have shown mixed results on superiority of carbetocin over oxytocin for the need for additional uterotonics and amount of blood loss, however, no significant effect on blood loss >1000 ml could be found. Most of the trials evaluating the prophylactic role of oxytocin and carbetocin after CD have focused on the low-risk PPH population. The incidence of biological risk factors for uterine atony such as multiple gestation (due to assisted reproductive techniques), and obesity has progressively increased in developed countries. There is still a lack of high-quality trials on the efficacy of carbetocin in high-risk parturients undergoing CD.
In this study, the investigators aim to compare the efficacy of carbetocin 100 mcg with oxytocin 5 IU bolus followed by continuous infusion of 250 mIU/min over 4 hours at elective CD in parturients with risk factors for uterine atony.
The comparative data is still lacking for both the agents as first-line uterotonics for patients having a high risk for uterine atony undergoing cesarean delivery. The result of this trial regarding the relative uterotonic efficacy and safety of the standardized prophylactic doses of both agents (carbetocin and oxytocin) will form the evidence base for future guidelines in high-risk parturients.
Inclusion criteria - Any one or more of the risk factors for uterine atony:
Overdistended uterus due to:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV oxytocin 5 IU diluted in 10 mL normal saline over 1 min followed by continuous infusion of 250 mIU/min over 4 hours.
Drug: Oxytocin
IV carbetocin 100 mcg diluted in 10 mL normal saline over 1 min followed by placebo infusion for 4 hours after the delivery of the fetus.
Drug: Carbetocin
Patient is given oxytocin 5 IU diluted in 10 mL normal saline, administered intravenously over 1 min, followed by continuous infusion of 250 mIU/min over 4 hours.
Also known as: Pitocin
Patient is given carbetocin 100 mcg diluted in 10 mL normal saline, administered intravenously over 1 min, followed by placebo infusion for 4 hours.
Also known as: Duratocin
Proportion of parturients requiring additional uterotonic agents intraoperatively
The proportion of patients who are administered additional uterotonic agents intraoperatively will be divided by the total number of patients assigned to the same treatment arm, for each of the 2 groups: oxytocin and carbetocin.
Time frame: 90 minutes
Uterine Tone 3 minutes
The intensity of uterine tone as evaluated by palpation of the uterus by the obstetrician at 3 minutes, from the completion of delivery of the drug, utilizing a verbal numeric rating scale of 0-10.
Time frame: 3 minutes
Uterine Tone 5 minutes
The intensity of uterine tone as evaluated by palpation of the uterus by the obstetrician at 5 minutes, from the completion of delivery of the drug, utilizing a verbal numeric rating scale of 0-10.
Time frame: 5 minutes
Uterine Tone 10 minutes
The intensity of uterine tone as evaluated by palpation of the uterus by the obstetrician at 10 minutes, from the completion of delivery of the drug, utilizing a verbal numeric rating scale of 0-10.
Time frame: 10 minutes
Calculated blood loss (CBL)
Blood loss will be calculated through the difference in hematocrit values assessed prior to and at the end of 24 hours after the cesarean section.
Time frame: 24 hours
Semi-quantitative blood loss (SQBL)
Blood loss measured in the operating room by volume (ml)
Time frame: 2 hours
Presence of blood transfusion
Number of units of blood product administered post-delivery
Time frame: 24 hours
Number of patients with ICU admission
Admission to the intensive care unit for bleeding post partum
Time frame: 24 hours
Number of patients with conservative surgical methods to manage post partum hemorrhage
Bakri balloon/B-Lynch sutures used intraoperatively
Time frame: 2 hours
Number of patients with radiological methods used to manage post partum hemorrhage
Uterine artery embolization used intraoperatively.
Time frame: 2 hours
Number of patients with surgical post partum hemorrhage management measures
Re-exploration for bleeding/uterine artery ligation/hysterectomy
Time frame: 2 hours
Number of patients with hypotension defined as systolic blood pressure less than 80% of baseline
Systolic blood pressure \< 80% of baseline, at any time during surgery
Time frame: 2 hours
Number of patients with hypertension defined as systolic blood pressure greater than 120% of baseline
Systolic blood pressure \> 120% of baseline, at any time during surgery
Time frame: 2 hours
Number of patients with tachycardia defined as heart rate greater than 130% of baseline
Heart rate \> 130% of baseline, at any time during surgery
Time frame: 2 hours
Number of patients with bradycardia defined as heart rate less than 70% of baseline
Heart rate \< 70% of baseline, at any time during surgery
Time frame: 2 hours
Presence of ventricular tachycardia: ECG
Presence of ventricular tachycardia as recorded by ECG, at any time during surgery
Time frame: 2 hours
Presence of atrial fibrillation: ECG
Presence of atrial fibrillation as recorded by ECG, at any time during surgery
Time frame: 2 hours
Presence of atrial flutter: ECG
Presence of atrial flutter as recorded by ECG, at any time during surgery
Time frame: 2 hours
Presence of nausea: questionnaire
The presence of nausea at any time during surgery, as reported by the patient
Time frame: 2 hours
Presence of vomiting: questionnaire
The presence of vomiting at any time during surgery, as reported by the patient
Time frame: 2 hours
Number of patients with chest pain: questionnaire
Any presence of chest pain, at any time during surgery, as reported by the patient
Time frame: 2 hours
Number of patients with shortness of breath: questionnaire
Any presence of shortness of breath, at any time during surgery, as reported by the patient.
Time frame: 2 hours
Number of patients with headache: questionnaire
Any presence of headache, at any time during surgery, as reported by the patient.
Time frame: 2 hours
Number of patients with flushing: questionnaire
Any presence of flushing, at any time during surgery.
Time frame: 2 hours
Additional uterotonics administered up to 24 hours post delivery: questionnaire
Were any additional uterotonics administered up to 24 hours post delivery: yes or no Detailed description of any medication and dosage recorded.
Time frame: 24 hours
Obstetric Quality of Recovery-10 (ObsQoR-10) score 24 hours
ObsQoR-10 score at 24 hours. There are 10 questions, and the results are tabulated out of 100. The higher the overall score out of 100, the better quality of recovery a patient is experiencing.
Time frame: 24 hours
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.
Of 112 non-industry interventional studies with no phase under Postpartum Hemorrhage, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 23 months is above that.
Counting every sponsor, half of 119 studies reached it within 16 months; a quarter within 7 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oxytocin · Carbetocin
Samuel Lunenfeld Research Institute, Mount Sinai Hospital →